"Totality-of-the-evidence" of proposed ustekinumab biosimilar SB17"

被引：0
|
作者：
Armuzzi, A. [1 ]
Girolomoni, G. [2 ]
Feldman, S. [3 ]
Goncalves, J. [4 ]
Park, Y. [5 ]
Ye, B. D. [6 ]
机构：
[1] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[2] Univ Verona, Dermatol, Verona, Italy
[3] Wake Forest Univ, Sch Med, Dermatol, Winston Salem, NC USA
[4] Univ Lisbon, Fac Pharm, Lisbon, Portugal
[5] Samsung Bioepis Co Ltd, Med Affairs, Incheon, South Korea
[6] Univ Ulsan, Coll Medicin, Gastroenterol Inflammatory Bowel Dis Ctr, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1019
引用
收藏
页码：I1832 / I1834
页数：3
相关论文
共 50 条
  • [21] 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
    Gaylis, Norman
    Both, Charlotte
    Lemke, Lena
    von Richter, Oliver
    Yamauchi, Paul
    [J]. ADVANCES IN THERAPY, 2024, 41 (05) : 1967 - 1982
  • [22] A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
    Reinisch, Walter
    Cohen, Stanley
    Ramchandani, Monica
    Khraishi, Majed
    Liu, Jennifer
    Chow, Vincent
    Franklin, Janet
    Colombel, Jean-Frederic
    [J]. ADVANCES IN THERAPY, 2022, 39 (01) : 44 - 57
  • [23] Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17
    Ombretta Viapiana
    Soohyun Lee
    SangWook Yoon
    Bruno Fautrel
    [J]. Clinical Drug Investigation, 2022, 42 : 103 - 112
  • [24] Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17
    Viapiana, Ombretta
    Lee, Soohyun
    Yoon, SangWook
    Fautrel, Bruno
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (02) : 103 - 112
  • [25] A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
    Walter Reinisch
    Stanley Cohen
    Monica Ramchandani
    Majed Khraishi
    Jennifer Liu
    Vincent Chow
    Janet Franklin
    Jean-Frederic Colombel
    [J]. Advances in Therapy, 2022, 39 : 44 - 57
  • [26] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Richard Markus
    Helen J. McBride
    Monica Ramchandani
    Vincent Chow
    Jennifer Liu
    Dan Mytych
    Gary Fanjiang
    [J]. Advances in Therapy, 2019, 36 : 1833 - 1850
  • [27] Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
    Kolberg, Hans-Christian
    Demetriou, Georgia Savva
    Hanes, Vladimir
    [J]. ONCOLOGY AND THERAPY, 2021, 9 (01) : 225 - 238
  • [28] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Markus, Richard
    McBride, Helen J.
    Ramchandani, Monica
    Chow, Vincent
    Liu, Jennifer
    Mytych, Dan
    Fanjiang, Gary
    [J]. ADVANCES IN THERAPY, 2019, 36 (08) : 1833 - 1850
  • [29] The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira
    Mcclellan, Joseph E.
    Omarsdottir, Sesselja
    Roy, Nivedita
    Berger, Verena
    Michel, Cecilia
    Berti, Fausto
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2024, 15
  • [30] A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
    Agarwala, Sanjiv S.
    Nagl, Ulrich
    Guo, Xinghua
    Bellon, Anne
    Heyn, Jens
    Dimova-Dobreva, Miryana
    Shen, Yu-Ming
    Schaffar, Gregor
    Humphrey, Martin
    Mathieson, Nicola
    Koptelova, Natalia
    Gattu, Sreekanth
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (06) : 999 - 1009
12345